TMO Stock Cash Flow Statements

Thermo Fisher Scientific Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Thermo Fisher Scientific Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-28	2025-03-29	2024-12-31	2024-09-28	2024-06-29	2024-03-30	2023-12-31	2023-09-30	2023-07-01	2023-04-01	2022-12-31	2022-10-01	2022-07-02	2022-04-02	2021-12-31	2021-10-02	2021-07-03	2021-04-03	2020-12-31	2020-09-26	2020-06-27	2020-03-28	2019-12-31	2019-09-28	2019-06-29	2019-03-30	2018-12-31	2018-09-29	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-07-01	2017-04-01	2016-12-31	2016-10-01	2016-07-02	2016-04-02

operating activities
net income	1,619,000,000	1,511,000,000	1,824,000,000	1,629,000,000	1,554,000,000	1,331,000,000	1,606,000,000	1,695,000,000	1,362,000,000	1,292,000,000	1,574,000,000	1,498,000,000	1,668,000,000	2,220,000,000	1,661,000,000	1,902,000,000	1,828,000,000	2,337,000,000	2,498,000,000	1,933,000,000	1,156,000,000	788,000,000	1,002,000,000	760,000,000	1,119,000,000	815,000,000	898,000,000	709,000,000	752,000,000	579,000,000	528,100,000	533,900,000	611,600,000	551,400,000	629,500,000	473,500,000	516,600,000	402,200,000
adjustments to reconcile net income to net cash from operating activities:
depreciation of property, plant and equipment	256,000,000	276,000,000	304,000,000	290,000,000	277,000,000	285,000,000	276,000,000	269,000,000	270,000,000	253,000,000	256,000,000	244,000,000	236,000,000	250,000,000	217,000,000	205,000,000	211,000,000	198,000,000	191,000,000	161,000,000	157,000,000	149,000,000	148,000,000	141,000,000	142,000,000	133,000,000
amortization of acquisition-related intangible assets	430,000,000	429,000,000	438,000,000	449,000,000	514,000,000	551,000,000	563,000,000	584,000,000	585,000,000	606,000,000	592,000,000	594,000,000	600,000,000	609,000,000	466,000,000	423,000,000	449,000,000	423,000,000	411,000,000	414,000,000	417,000,000	425,000,000	428,000,000	434,000,000	429,000,000	422,000,000
change in deferred income taxes	-322,000,000	-279,000,000	-202,000,000	-400,000,000	-354,000,000	-253,000,000	-669,000,000	-303,000,000	-182,000,000	-146,000,000	-133,000,000	-261,000,000	-262,000,000	-339,000,000	-192,000,000	-148,000,000	-331,000,000	24,000,000	-56,000,000	-178,000,000	-277,000,000	-41,000,000
stock-based compensation	81,000,000	75,000,000	79,000,000	68,000,000	84,000,000	70,000,000	61,000,000	67,000,000	74,000,000	76,000,000	75,000,000	77,000,000	77,000,000	78,000,000	77,000,000	51,000,000	51,000,000	51,000,000	51,000,000	52,000,000	47,000,000	46,000,000
other net non-cash expenses	63,000,000	135,000,000
changes in assets and liabilities, excluding the effects of acquisitions	-726,000,000	-1,425,000,000		30,000,000	-216,000,000	-787,000,000		-9,000,000	-718,000,000	-1,533,000,000		-367,000,000	-849,000,000	-875,000,000		237,000,000	-126,000,000	-1,321,000,000
net cash from operating activities	1,399,000,000	723,000,000	3,290,000,000	2,166,000,000	1,960,000,000	1,251,000,000	3,723,000,000	2,414,000,000	1,540,000,000	729,000,000	3,487,000,000	1,937,000,000	1,528,000,000	2,202,000,000	2,457,000,000	2,650,000,000	2,227,000,000	1,978,000,000	3,339,000,000	2,708,000,000	1,886,000,000	356,000,000	1,913,000,000	1,117,000,000	1,294,000,000	649,000,000	1,801,000,000	1,220,000,000	1,444,000,000	78,000,000	1,866,500,000	928,600,000	848,400,000	361,500,000	1,205,900,000	771,800,000	889,500,000	289,100,000
capex	-294,000,000	-362,000,000	-480,000,000	-272,000,000	-301,000,000	-347,000,000	-405,000,000	-332,000,000	-284,000,000	-458,000,000	-550,000,000	-547,000,000	-506,000,000	-640,000,000	-831,000,000	-524,000,000	-540,000,000	-628,000,000	-586,000,000	-366,000,000	-269,000,000	-253,000,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
free cash flows	1,105,000,000	361,000,000	2,810,000,000	1,894,000,000	1,659,000,000	904,000,000	3,318,000,000	2,082,000,000	1,256,000,000	271,000,000	2,937,000,000	1,390,000,000	1,022,000,000	1,562,000,000	1,626,000,000	2,126,000,000	1,687,000,000	1,350,000,000	2,753,000,000	2,342,000,000	1,617,000,000	103,000,000	1,913,000,000	1,117,000,000	1,294,000,000	649,000,000	1,801,000,000	1,220,000,000	1,444,000,000	78,000,000	1,866,500,000	928,600,000	848,400,000	361,500,000	1,205,900,000	771,800,000	889,500,000	289,100,000
investing activities
purchases of property, plant and equipment	-294,000,000	-362,000,000	-480,000,000	-272,000,000	-301,000,000	-347,000,000
proceeds from sale of property, plant and equipment	1,000,000	12,000,000	17,000,000	20,000,000	16,000,000	4,000,000	11,000,000	66,000,000	4,000,000	6,000,000	6,000,000	4,000,000	12,000,000	2,000,000	11,000,000	4,000,000	0	5,000,000	1,000,000	1,000,000	2,000,000	4,000,000	18,000,000	6,000,000	6,000,000	6,000,000	44,000,000	3,000,000	1,000,000	2,000,000	2,700,000	2,000,000	1,200,000	1,100,000	3,200,000	1,400,000	15,700,000	6,000,000
proceeds from cross-currency interest rate swap interest settlements	47,000,000	87,000,000	49,000,000	92,000,000	47,000,000	64,000,000
purchases of investments	-47,000,000	-264,000,000	-1,331,000,000	-287,000,000	-20,000,000	-1,758,000,000
other investing activities	5,000,000	1,000,000	-6,000,000	2,000,000	5,000,000	7,000,000	-52,000,000	-6,000,000	-116,000,000	14,000,000	19,000,000	-3,000,000	75,000,000	8,000,000	4,000,000	-2,000,000	-4,000,000	-32,000,000				-7,000,000	88,000,000	11,000,000	4,000,000	15,000,000												2,200,000
net cash from investing activities	-288,000,000	-527,000,000	20,000,000	-3,578,000,000	-253,000,000	-2,030,000,000	-376,000,000	-1,181,000,000	-443,000,000	-3,142,000,000	-525,000,000	-545,000,000	-419,000,000	-670,000,000	-18,692,000,000	-616,000,000	-626,000,000	-1,998,000,000	-626,000,000	-365,000,000	-259,000,000	-260,000,000						-168,000,000	-185,000,000	-179,000,000	-283,400,000	-6,968,300,000	-95,400,000	-381,900,000	-88,100,000	-4,196,000,000	-108,700,000	-1,139,300,000
financing activities
net proceeds from issuance of debt	0	2,840,000,000	0	0	-1,000,000	1,205,000,000	2,476,000,000								15,015,000,000				0	0	1,279,000,000	2,185,000,000					0				0	5,940,100,000	-100,000	519,000,000	-1,800,000	5,620,200,000	986,700,000	998,900,000
repayment of debt	-787,000,000	-838,000,000	-2,500,000,000				-3,782,000,000	-1,000,000,000			0	0	0	-375,000,000	-8,931,000,000	-2,000,000	-1,000,000	-2,804,000,000	-1,000,000	-710,000,000	-1,000,000	-1,000,000
purchases of company common stock	0	-2,000,000,000	-1,000,000,000	0	0	-3,000,000,000	0	0	0	-3,000,000,000	-1,000,000,000	0	0	-2,000,000,000	0	0	0	-2,000,000,000	0	0	0	-1,500,000,000
dividends paid	-162,000,000	-149,000,000	-149,000,000	-150,000,000	-149,000,000	-135,000,000	-136,000,000	-135,000,000	-135,000,000	-117,000,000	-117,000,000	-118,000,000	-117,000,000	-103,000,000	-103,000,000	-102,000,000	-103,000,000	-87,000,000	-87,000,000	-87,000,000	-87,000,000	-76,000,000
other financing activities	-42,000,000	45,000,000	-17,000,000	67,000,000	35,000,000	110,000,000	14,000,000	18,000,000	4,000,000	20,000,000	77,000,000	-38,000,000	-12,000,000	-36,000,000	-81,000,000	-7,000,000	-24,000,000	21,000,000	-1,000,000	-25,000,000	-23,000,000	-98,000,000
net cash from financing activities	-991,000,000	-102,000,000	-3,666,000,000	-1,190,000,000	-115,000,000	-1,821,000,000	-1,428,000,000	1,855,000,000	-1,456,000,000	-2,593,000,000	2,391,000,000	-151,000,000	-1,905,000,000	-3,145,000,000	8,467,000,000	3,040,000,000	-76,000,000	-4,850,000,000	-49,000,000	-791,000,000	1,180,000,000	619,000,000									-1,144,300,000				-2,191,500,000	4,753,300,000	-889,200,000	1,188,000,000
exchange rate effect on cash	311,000,000	37,000,000	-273,000,000	175,000,000	-15,000,000	22,000,000	10,000,000	-73,000,000	12,000,000	-31,000,000	250,000,000	-212,000,000	-78,000,000	-99,000,000	211,000,000	-61,000,000	-93,000,000	137,000,000	102,000,000	181,000,000	20,000,000	-127,000,000								57,000,000	163,900,000	87,900,000	102,400,000	65,800,000				36,900,000
increase in cash, cash equivalents and restricted cash	431,000,000	132,000,000									5,603,000,000				-7,557,000,000	5,013,000,000	1,432,000,000	-4,733,000,000	2,766,000,000	1,733,000,000	2,827,000,000	588,000,000
cash, cash equivalents and restricted cash at beginning of period	0	4,040,000,000		0	0	8,097,000,000		0	0	8,537,000,000		0	0	4,491,000,000		0	0	10,336,000,000		0	0	2,422,000,000	0	0	0	2,117,000,000	0	0	0	1,361,000,000	200,000	0	0	810,800,000
cash, cash equivalents and restricted cash at end of period	431,000,000	4,172,000,000		-2,427,000,000	1,578,000,000	5,519,000,000		3,015,000,000	-347,000,000	3,500,000,000		1,029,000,000	-874,000,000	2,779,000,000		5,013,000,000	1,432,000,000	5,603,000,000		1,733,000,000	2,827,000,000	3,010,000,000	1,117,000,000	-1,009,000,000	1,186,000,000	1,128,000,000	1,006,000,000	155,000,000	-19,000,000	975,000,000	602,900,000	128,800,000	-107,600,000	736,900,000
changes in assets and liabilities, excluding the effects of acquisitions:
accounts receivable																			-444,000,000	-663,000,000	23,000,000	-218,000,000
inventories																			-81,000,000	-118,000,000	-168,000,000	-141,000,000													75,500,000
contract assets/liabilities
accounts payable																			279,000,000	277,000,000	-256,000,000	-241,000,000	196,000,000										-65,000,000	114,000,000	-10,600,000	26,200,000	5,100,000	34,800,000
contributions to retirement plans																			-51,000,000	-9,000,000	-4,000,000	-32,000,000
other																			410,000,000	739,000,000	746,000,000	-443,000,000
acquisitions, net of cash acquired			0				0	-909,000,000	-47,000,000	-2,704,000,000	0	1,000,000	0	-40,000,000	-17,876,000,000	-94,000,000	-82,000,000	-1,343,000,000	-35,000,000	0	1,000,000	-4,000,000
proceeds from sales and maturities of investments
proceeds from issuance of commercial paper							0	0	593,000,000	1,027,000,000	295,000,000	199,000,000	406,000,000	626,000,000					0	0	1,000,000	382,000,000	200,000,000	686,000,000	1,795,000,000	100,000,000	1,682,000,000	617,000,000	1,455,000,000	1,306,000,000
repayments of commercial paper							0	-494,000,000	-918,000,000	-523,000,000	0	-200,000,000	-2,231,000,000	-1,259,000,000					0	0	-66,000,000	-321,000,000
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
other non-cash expenses				97,000,000	104,000,000	53,000,000	163,000,000	111,000,000	149,000,000	181,000,000	81,000,000	152,000,000	58,000,000	233,000,000	-4,000,000	-20,000,000	145,000,000	69,000,000	131,000,000	100,000,000	45,000,000	64,000,000	-39,000,000	75,000,000	30,000,000	18,000,000	39,000,000	12,000,000	31,000,000	24,000,000	36,300,000	21,400,000	17,000,000	28,300,000	17,800,000	22,900,000	11,900,000	14,200,000
decrease in cash, cash equivalents and restricted cash				-2,427,000,000	1,578,000,000	-2,578,000,000		3,015,000,000	-347,000,000	-5,037,000,000			-874,000,000	-1,712,000,000
loss on early extinguishment of debt											0	0	0	26,000,000	570,000,000	0	0	197,000,000
purchase of property, plant and equipment							-405,000,000	-332,000,000	-284,000,000	-458,000,000	-550,000,000	-547,000,000	-506,000,000	-640,000,000	-831,000,000	-524,000,000	-540,000,000	-628,000,000	-586,000,000	-366,000,000	-269,000,000	-253,000,000
changes in assets and liabilities, excluding the effects of acquisitions and disposition:
net proceeds from issuance of company common stock under employee stock plans												6,000,000	49,000,000	2,000,000	55,000,000	29,000,000	52,000,000	20,000,000	40,000,000	31,000,000	77,000,000	48,000,000	38,000,000	-7,000,000	41,000,000	81,000,000	39,000,000	19,000,000	39,000,000	39,000,000	20,300,000	8,600,000	40,900,000	58,200,000	12,800,000	24,600,000	47,900,000	50,000,000
gain on sales of businesses
proceeds from sale of business, net of cash divested																							0	2,000,000
income from discontinued operations																															2,400,000	0			3,200,000	0	200,000	100,000
income from continuing operations																											898,000,000	709,000,000			530,500,000	533,900,000	612,200,000	551,400,000	632,700,000	473,500,000	516,800,000	402,300,000
adjustments to reconcile income from continuing operations to net cash from operating activities:
non-cash stock-based compensation																							43,000,000	42,000,000	52,000,000	44,000,000	44,000,000	46,000,000	48,000,000	43,000,000	43,100,000	44,700,000	38,200,000	33,000,000	31,500,000	34,900,000	33,700,000	33,400,000
other assets
other liabilities																							38,000,000	-147,000,000							992,600,000
net cash from continuing operations																											1,801,000,000	1,220,000,000	1,444,000,000	78,000,000	1,865,700,000	929,300,000	848,600,000	362,400,000	1,204,900,000	772,900,000	889,900,000	290,600,000
net cash from discontinued operations
net proceeds from issuance of company common stock																															-300,000
gain on sale of business
depreciation and amortization																											558,000,000	563,000,000	571,000,000	575,000,000	573,500,000	516,800,000	478,200,000	464,500,000	473,800,000	433,000,000	435,100,000	416,100,000
non-cash charges for sale of inventories revalued at the date of acquisition																												2,000,000	5,000,000	3,000,000	39,700,000	16,200,000	400,000	30,700,000	36,300,000	16,300,000	16,200,000	6,200,000
changes in assets and liabilities, excluding the effects of acquisitions and dispositions:
see note 12 for supplemental cash flow information.
proceeds from sale of investments																															3,500,000	2,000,000	4,800,000	11,700,000
see note 13 for supplemental cash flow information.
net proceeds from issuance of commercial paper																																1,543,100,000	2,126,000,000	2,361,100,000
net gains on sale of businesses
tax benefits from stock-based compensation awards																																			-1,400,000	10,300,000	17,400,000	27,200,000
proceeds from sale of businesses, net of cash divested
increase in restricted cash
increase in commercial paper																																			135,300,000	-167,300,000	-237,900,000	1,174,000,000
increase in cash and cash equivalents																																			-1,183,800,000	1,306,900,000	-163,700,000	374,700,000
cash and cash equivalents at beginning of period																																			0	0	0	452,100,000
cash and cash equivalents at end of period																																			-1,183,800,000	1,306,900,000	-163,700,000	826,800,000
decrease in restricted cash
net proceeds from issuance of long-term debt
repayment of long-term obligations
decrease in short-term notes payable
loss on disposal of discontinued operations
decrease (increase) in restricted cash
increase in short-term notes payable
loss (income) from discontinued operations
gain on disposal of discontinued operations
and dispositions:
proceeds from derivative instruments related to phadia acquisition
settlement of convertible debt
redemption and repayment of long-term obligations
(gain) loss on disposal of discontinued operations
non-cash interest expense on convertible debt
net cash from discounted operations
exchange rate effect on cash of continuing operations
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
purchase of available-for-sale investments
proceeds from sale of available-for-sale investments
distribution from retirement trust to fund disbursements
collection of notes receivable
increase in other assets
non-cash charges for the sale of inventories revalued at the date of acquisition
cash acquired in fisher merger, net of transaction costs
purchases of available-for-sale investments
proceeds from maturities of available-for-sale investments
proceeds from sale of product lines and businesses, net of cash divested
revenues
costs and operating expenses:
cost of revenues
selling, general and administrative expenses
research and development expenses
restructuring and other costs
operating income
other income
income from continuing operations before benefit from income taxes
benefit from income taxes
earnings per share from continuing operations
basic
diluted
earnings per share
weighted-average shares
assets
current assets:
cash and cash equivalents
short-term investments, at quoted market value
accounts receivable, less allowances of 49.5 and 45.0
deferred tax assets
other current assets
property, plant and equipment, at cost
acquisition-related intangible assets
goodwill
liabilities and shareholders’ equity
current liabilities:
short-term obligations and current maturities of long-term obligations
accrued payroll and employee benefits
accrued income taxes
deferred revenue
other accrued expenses
deferred income taxes
other long-term liabilities
long-term obligations
commitments and contingencies
shareholders’ equity
preferred stock, 100 par value, 50,000 shares authorized; none issued
common stock, 1 par value, 1,200,000,000 shares authorized; 439,340,851 and 424,420,292 shares issued
capital in excess of par value
retained earnings
treasury stock at cost, 24,102,880 and 7,635,184 shares
accumulated other comprehensive items
non-cash restructuring and other costs
gain on investments
non-cash equity compensation
tax benefits from exercised stock options
other current liabilities
refund of acquisition purchase price
borrowings under short-term bridge financing agreements
repayment of bridge financing agreement
comprehensive income
other comprehensive items
currency translation adjustment
unrealized gains on available-for-sale investments, net of reclassification adjustment and net of tax
unrealized gains on hedging instruments, net of tax
pension and other postretirement benefit liability adjustments, net of tax
common stock, 1 par value:
balance at beginning of year
issuance of shares for merger with fisher
issuance of shares for conversion of debt
retirement of treasury shares
issuance of stock under employees’ and directors’ stock plans
balance at end of year
capital in excess of par value:
elimination of deferred compensation
issuance of equity for merger with fisher
fair value of fisher convertible debt allocable to equity
activity under employees’ and directors’ stock plans
equity compensation
tax benefit related to employees’ and directors’ stock plans
retained earnings:
treasury stock:
deferred compensation
awards under employees’ stock plans
amortization of deferred compensation
initial impact upon adoption of sfas no. 158, net of taxes
note 1.
balance at december 31, 2005
provision charged to income
usage
acquisitions
adjustments to previously provided warranties
balance at december 31, 2006
balance at december 31, 2007
raw materials
work in progress
finished goods
land
buildings and improvements
machinery, equipment and leasehold improvements
less: accumulated depreciation and amortization
2007
definite lives:
customer relationships
product technology
tradenames
patents
indefinite lives:
2006
2008
2009
2010
2011
2012
2013 and thereafter
finalization of purchase price allocation for kendro
write off due to sale of businesses
currency translation
finalization of purchase price allocation for fisher and cohesive
tax benefits from exercise of stock options
write off due to planned sale of business
contribution of businesses to joint ventures
total assets
total current liabilities
total liabilities
total shareholders’ equity
note 2.
purchase price:
cash paid
purchase price payable
cash acquired
allocation:
current assets
property, plant and equipment
tradenames and other
liabilities assumed
includes transaction costs.
fair value of common stock issued to fisher shareholders
fair value of fisher stock options and warrants converted into options in company common stock
debt assumed
cash paid including transaction costs
acquired intangible assets
fair value of convertible debt allocable to equity
trademarks
includes transaction costs, subsequent payments of contingent consideration and cash settlements of post-closing adjustments.
includes acquisition expenses, subsequent payments of contingent consideration and cash settlements of post-closing adjustments.
earnings per share from continuing operations:
earnings per share:
includes 121 million pre-tax charge to cost of revenues for the sale of fisher inventories revalued at the date of merger, 15 million pre-tax charge for fisher’s in-process research and development and 37 million pre-tax charge for accelerated vesting of stock-based awards resulting from the change in control occurring at the date of the fisher merger.
balance at december 31, 2004
reserved established
payments
decrease recorded as a reduction in goodwill
divestiture of product line
reserves reclassified to long-term asset retirement obligations
note 3.
revenues:
analytical technologies
laboratory products and services
eliminations
consolidated revenues
operating income:
subtotal reportable segments
cost of revenues charges
stock-based compensation acceleration charge
consolidated operating income
total assets:
corporate/other
consolidated total assets
amortization:
consolidated amortization
depreciation:
consolidated depreciation
capital expenditures
consolidated capital expenditures
united states
germany
england
transfers among geographical areas
long-lived assets
export sales included in united states revenues above
represents operating income before certain charges to cost of revenues; restructuring and other costs, net; amortization of acquisition-related intangibles; and stock-based compensation acceleration expense.
revenues are attributed to countries based on selling location.
transfers among geographical areas are accounted for at prices that are representative of transactions with unaffiliated parties.
includes property, plant and equipment, net.
in general, export revenues are denominated in u.s. dollars.
note 4.
interest income
interest expense
equity in earnings of unconsolidated subsidiaries
other items
note 5.
stock option awards
restricted share/unit awards
total stock-based compensation expense
includes 33.8 million and 2.9 million of stock option and restricted share expense, respectively, resulting from the accelerated vesting upon the change of control that occurred as a result of the fisher merger.
prior to the adoption of sfas no. 123r compensation cost related to stock options was not recognized in the statement of income.
includes 3.8 million, 30.8 million, and 2.1 million of cost of revenues, selling, general and administrative and research and development expense resulting from the accelerated vesting upon the change of control that occurred as a result of the fisher merger.
expected stock price volatility
risk free interest rate
expected life of options
expected annual dividend per share
outstanding at december 31, 2004
granted
exercised
canceled/expired
outstanding at december 31, 2005
issued in connection with fisher merger
canceled
expired
outstanding at december 31, 2006
outstanding at december 31, 2007
vested and unvested expected to vest at december 31, 2007
exercisable at december 31, 2007
unvested at december 31, 2005
vesting
unvested at december 31, 2006
forfeited
unvested at december 31, 2007
income from continuing operations:
as reported
add: stock-based employee compensation expense included in reported results, net of tax
deduct: total stock-based employee compensation expense determined under the fair-value-based method for all awards, net of tax
pro forma
basic earnings per share from continuing operations:
diluted earnings per share from continuing operations:
net income:
add: stock-based employee compensation expense included in reported net income, net of tax
basic earnings per share:
diluted earnings per share:
change in projected benefit obligations
benefit obligation at beginning of year
business combination
service costs
interest costs
plan amendment
plan participants’ contribution
actuarial (gains) losses
benefits paid
currency translation and other
benefit obligation at end of year
change in fair value of plan assets
fair value of plan assets at beginning of year
actual return on plan assets
employer contribution
plan participants’ contributions
fair value of plan assets at end of year
funded status
accumulated benefit obligation
amounts recognized in consolidated balance sheet consist of:
non-current asset
current liability
non-current liability
net amount recognized
amounts recognized in accumulated other comprehensive (income) loss consist of:
net actuarial (gain) loss
prior service costs
weighted-average assumptions used to determine projected benefit obligations
discount rate
average rate of increase in employee compensation
weighted-average assumptions used to determine the net benefit cost
expected long-term rate of return on assets
change in benefit obligations
amounts recognized in accumulated other comprehensive income consist of:
weighted-average assumptions used to determine benefit obligations
initial healthcare cost trend rate
ultimate healthcare cost trend rate
net actuarial loss
net prior service costs
pension plans with projected benefit obligations in excess of plan assets
projected benefit obligation
fair value of plan assets
pension plans with accumulated benefit obligations in excess of plan assets
components of net periodic benefit cost
service cost-benefits earned
interest cost on benefit obligation
expected return on plan assets
recognized actuarial net (gain) loss
amortization of prior service benefit
settlement/curtailment (gain) loss
special termination benefit recognized
net periodic benefit cost
2013-2017
equity securities
debt securities
insurance policies
real estate
cash and other
one percentage point:
effect on total of service and interest cost components
effect on postretirement healthcare benefit obligation
note 6.
u.s.
non-u.s.
income tax provision
federal
state
deferred income tax provision
continuing operations
discontinued operations
benefit from income taxes at statutory rate
increases (decreases) resulting from:
foreign rate differential
change in tax laws
income tax credits
extraterritorial income exclusion
manufacturing deduction
basis difference of businesses sold or terminated
state income taxes, net of federal tax
nondeductible expenses
fin 48 reserves
tax return reassessments and settlements
deferred tax asset
net operating income and credit carryforwards
reserves and accruals
accrued compensation
inventory basis difference
available-for-sale investments
less: valuation allowance
additions for tax positions of current year
closure of tax years
note 7.
net income for basic earnings per share
effect of convertible debentures
income available to common shareholders, as adjusted for diluted earnings per share
basic weighted-average shares
effect of:
convertible debentures
stock options, restricted stock awards and warrants
diluted weighted-average shares
principal outstanding
conversion price per share
trigger price
future common stock price
23.73
24.73
29.55
30.55
40.20
41.20
50.00
55.00
60.00
65.00
70.00
note 8.
cumulative translation adjustment
net unrealized gain on available-for-sale investments
net unrealized losses on hedging instruments
pension and other postretirement benefit liability adjustments
note 9.
auction rate securities
note 10.
revolving credit facility
money market loans
2.50% senior convertible notes, due 2023 convertible at 23.73 per share
floating rate senior convertible debentures, due 2033 convertible at 29.55 per share
3.25% senior subordinated convertible notes, due 2024 convertible at 40.20 per share
5% senior notes, due 2015
7 5/8% senior notes, due 2008
6 3/4% senior subordinated notes, due 2014
6 1/8% senior subordinated notes, due 2015
3.25% subordinated convertible debentures, due 2007, convertible at 41.84 per share
less: short-term obligations and current maturities
note 11.
thereafter
future minimum lease payments
note 12.
note 13.
notes receivable
long-term obligations:
convertible obligations
senior notes
senior subordinated notes
forward currency-exchange contracts receivable
note 14.
cash paid for:
interest
income taxes
non-cash activities
fair value of assets of acquired businesses and product lines
cash paid for acquired businesses and product lines
fair value of common stock issued
fair value of options and warrants
liabilities assumed of acquired businesses and product lines
conversion of subordinated convertible debentures
issuance of restricted stock
issuance of stock upon vesting of restricted stock units
note 15.
pre-2006 restructuring plans
costs incurred in 2005
reserves reversed
costs incurred in 2006
costs incurred in 2007
2006 restructuring plans
2007 restructuring plans
employee-retention costs are accrued ratably over the period through which employees must work to qualify for a payment.
represents reductions in cost of plans as described in the discussion of restructuring actions by segment.
excludes net gains of 7.8 million from the sale of six abandoned buildings, non-cash charges of 1.7 million and a gain of 0.3 million from the sale of a small non-core business.
excludes non-cash charges, net, of 17.4 million and net gains from the sale of abandoned assets of 1.9 million.
excludes non-cash charges, net of 1.9 million and a loss of 1.7 million from the sale of a business. also excludes a net gain of 1.0 million from pension plan curtailments.
note 16.
note 17.
gross profit
costs of 43.8 million and after-tax income of 0.1 million related to the company’s discontinued operations.
costs of 19.5 million and after-tax loss of 24.0 million related to the company’s discontinued operations.
costs of 9.2 million and after-tax loss of 0.1 million related to the company’s discontinued operations.
costs of 18.9 million and after-tax income of 5.5 million related to the company’s discontinued operations.
costs of 3.6 million and after-tax income of 3.3 million related to the company’s discontinued operations.
costs of 6.0 million and after-tax loss of 1.1 million related to the company’s discontinued operations.
costs of 7.2 million.
costs of 106.5 million and after-tax income of 0.4 million related to the company’s discontinued operations.
allowance for doubtful accounts
year ended december 31, 2007
year ended december 31, 2006
year ended december 31, 2005
accrued acquisition expenses
accrued restructuring costs
includes allowance of businesses acquired and sold during the year as described in note 2 and the effect of currency translation.
the nature of activity in this account is described in note 2.
represents reversal of accrued acquisition expenses and corresponding reduction of goodwill or other intangible assets resulting from finalization of restructuring plans and the effect of currency translation.
the nature of activity in this account is described in note 15.
represents the effect of currency translation.
schedule ii – valuation and qualifying accounts

We provide you with 20 years of cash flow statements for Thermo Fisher Scientific stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Thermo Fisher Scientific stock. Explore the full financial landscape of Thermo Fisher Scientific stock with our expertly curated income statements.

The information provided in this report about Thermo Fisher Scientific stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.